Safety issues in the development of treatments for osteoarthritis: Recommendations of the Safety Considerations Working Group

Osteoarthritis and Cartilage

Volumn 19, Issue 5, 2011, Pages 493-499

  Strand, V ^a   Bloch, D A ^a   Leff, R ^b   Peloso, P M ^c   Simon, L S ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Merck Research Laboratories ^*

^c SDG LLC   (United States)

Author keywords

Cardiovascular risks; COX 2; NSAIDs; Safety assessments; Serious adverse events

Indexed keywords

CELECOXIB; DICLOFENAC; DISEASE MODIFYING ANTIRHEUMATIC DRUG; IBUPROFEN; NAPROXEN;

ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; COHORT ANALYSIS; DATA BASE; DIABETES MELLITUS; DISEASE COURSE; DRUG EXPOSURE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FINANCIAL MANAGEMENT; FUNDING; HUMAN; OSTEOARTHRITIS; PALLIATIVE THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; RISK ASSESSMENT; STATISTICAL ANALYSIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; HUMANS; OSTEOARTHRITIS; PRACTICE GUIDELINES AS TOPIC; PRODUCT SURVEILLANCE, POSTMARKETING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK ASSESSMENT;

EID: 79955828357     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2011.02.019     Document Type: Article

References (57)

1. Altman R.D. Practical considerations for the pharmacologic management of osteoarthritis. Am J Manag Care 2009, 15(Suppl 8):S236-S243.
2. Beaulieu M., Choquette D., Rahme E., Bessette L., Carrier R. CURATA: A patient health management program for the treatment of osteoarthritis in Québec: an integrated approach to improving the appropriate utilization of anti-inflammatory/analgesic medications. Am J Manag Care 2004, 10:569-575.
3. Becker M.C., Wang T.H., Wisniewski L., Wolski K., Libby P., Lüscher T.F., et al. Rationale, design, and governance of prospective randomized evaluation of celecoxib integrated safety versus ibuprofen or naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. Am Heart J 2009, 157:606-612.
4. Berlin J.A., Glasser S.C., Ellenberg S.S. Adverse event detection in drug development: recommendations and obligations beyond phase 3. Am J Public Health 2008, 98:1366-1371.
5. Beyth R.J., Shorr R.I. Epidemiology of adverse drug reactions in the elderly by drug class. Drugs Aging 1999, 14:231-239.
6. Blackshear J.L., Davidman M., Stillman M.T. Identification of risk for renal insufficiency from nonsteroidal anti-inflammatory drugs. Arch Intern Med 1983, 143:1130-1134.
7. Brewster W., Gibbs T., Lacroix K., Murray A., Tydeman M., Almenoff J. Evolving paradigms in pharmacovigilance. Curr Drug Saf 2006, 1:127-134.
8. Brouwers J.R., de Smet P.A. Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs. Clin Pharm 1994, 27:462-485.
9. Chan A.T., Manson J.E., Albert C.M., Chae C.U., Rexrode K.M., Curhan G.C., et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 2006, 113:1578-1587.
10. Cimmino M.A., Sarzi-Puttini P., Scarpa R., Caporali R., Parazzini F., Zaninelli A., et al. Clinical presentation of osteoarthritis in general practice: determinants of pain in Italian patients in the AMICA study. Semin Arthritis Rheum 2005, 35(Suppl 1):17-23.
11. Cunnington M., Webb D., Qizilbash N., Blum D., Mander A., Funk M.J., et al. Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis. Pharmacoepidemiol Drug Saf 2008, 17:601-608.
12. Curhan G.C., Willett W.C., Rosner B., Stampfer M.J. Frequency of analgesic use and risk of hypertension in younger women. Arch Intern Med 2002, 162:2204-2208.
13. Di Y.M., Li C.G., Xue C.C., Zhou S.F. Clinical drugs that interact with St. John's wort and implication in drug development. Curr Pharm Des 2008, 14:1723-1742.
14. Dziedzic K.S., Hill J.C., Porcheret M., Croft P.R. New models for primary care are needed for osteoarthritis. Phys Ther 2009, 89:1371-1378.
15. Erb N., Pace A.V., Douglas K.M., Banks M.J., Kitas G.D. Risk assessment for coronary heart disease in rheumatoid arthritis and osteoarthritis. Scand J Rheumatol 2004, 33:293-299.
16. Figueiras A., Tato F., Fontaiñas J., Gestal-Otero J.J. Influence of physicians' attitudes on reporting adverse drug events: a case-control study. Med Care 1999, 37:809-814.
17. Food and Drug Administration Federal Register Notice. Docket No.1998D-0077 [formerly 98D-0077]; August 14, 2007.
18. clinical development programs for drugs, devices, and biological products intended for the treatment of osteoarthritis (OA) FDA Guidance for Industry. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071577.pdf.
19. Guidance for industry diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention HHS/FDA/CDER DRAFT FDA. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071624.pdf.
20. Guidance for industry diabetes mellitus - evaluating cardiovascular risk in antidiabetic therapies to treat type 2 diabetes FDA. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf.
21. FDA Product Labeling: adalimumab. http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/125057s0110lbl.pdf.
22. FDA Product Labeling: abatacept. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125118s0086lbl.pdf.
23. FDA Product Labeling: tocilizumab. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125276lbl.pdf.
24. Fosbøl E.L., Folke F., Jacobsen S., Rasmussen J.N., Sørensen R., Schramm T.K., et al. Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals. Circulation: Circ Cardiovasc Qual Outcomes 2010, 3:395-405.
25. Fosbøl E.L., Gislason G.H., Jacobsen S., Folke F., Hansen M.L., Schramm T.K., et al. Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther 2009, 85:190-197.
26. Furst D.E. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2010, 39:327-346.
27. Glasser S.P., Salas M., Delzell E. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems. J Clin Pharmacol 2007, 47:1074-1086.
28. Hammond I.W., Gibbs T.G., Seifert H.A., Rich D.S. Database size and power to detect safety signals in pharmacovigilance. Expert Opin Drug Saf 2007, 6:713-721.
29. Hernández-Díaz S., Varas-Lorenzo C., García Rodríguez L.A. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 2006, 98:266-274.
30. Hochberg M.C., Perlmutter D.L., Hudson J.I., Altman R.D. Preferences in the management of osteoarthritis of the hip and knee: results of a survey of community-based rheumatologists in the United States. Arthritis Care Res 1996, 9:170-176.
31. ICH Guidelines: the Extent of Population Exposure to Assess Clinical Safety for Drugs Intended for Long-Term Treatment of Non-Life Threatening Conditions. E1; http://www.ich.org/LOB/media/MEDIA435.pdf.
32. Jordan K.M., Arden N.K., Doherty M., Bannwarth B., Bijlsma J.W., Dieppe P., et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003, 62:1145-1155.
33. Lanas A., Tornero J., Zamorano J.L. Assessment of gastrointestinal and cardiovascular risk in patients with osteoarthritis who require NSAIDs: the LOGICA study. Ann Rheum Dis 2010, 69:1453-1458.
34. Lawrence R.C., Felson D.T., Helmick C.G., Arnold L.M., Choi H., Deyo R.A., et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Arthritis Rheum 2008, 58:26-35. Part II.
35. Lee J.H., Slifman N.R., Gershon S.K., Edwards E.T., Schwieterman W.D., Siegel J.N., et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002, 46:2565-2570.
36. Lipscomb E.R., Finch E.A., Brizendine E., Saha C.K., Hays L.M., Ackermann R.T. Reduced 10-year risk of coronary heart disease in patients who participated in a community-based diabetes prevention program: the DEPLOY pilot study. Diabetes Care 2009, 32:394-396.
37. Lopez-Gonzalez E., Herdeiro M.T., Figueiras A. Determinants of under-reporting of adverse drug reactions: a systematic review. Drug Saf 2009, 32:19-31.
38. Mazer M., Perrone J. Acetaminophen-induced nephrotoxicity: pathophysiology, clinical manifestations, and management. J Med Toxicol 2008, 4:2-6.
39. McClain C.J., Price S., Barve S., Devalarja R., Shedlofsky S. Acetaminophen hepatotoxicity: an update. Curr Gastroenterol Rep 1999, 1:42-49.
40. McGettigan P., Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. J Am Med Assoc 2006, 296:1633-1644.
41. Osteoarthritis National Clinical Guideline for Care and Management in Adults 2008, The National Collaborating Centre for Chronic Conditions. http://www.nice.org.uk/nicemedia/pdf/CG059FullGuideline.pdf.
42. Niculescu L., Li C., Huang J., Mallen S. Pooled analysis of GI tolerability of 21 randomized controlled trials of celecoxib and nonselective NSAIDs. Curr Med Res Opin 2009, 25:729-740.
43. Pergolizzi J., Böger R.H., Budd K., Dahan A., Erdine S., Hans G., et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 2008, 8:287-313.
44. Ray W.A., Varas-Lorenzo C., Chung C.P., Castellsague J., Murray K.T., Stein C.M., et al. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circulation: Cardiovascular Quality and Outcomes 2009, 2:155-163.
45. Roujeau J.C. Clinical aspects of skin reactions to NSAIDs. Scand J Rheumatol 1987, 65:131-134.
46. Roumie C.L., Choma N.N., Kaltenbach L., Mitchel E.F., Arbogast P.G., Griffin M.R. Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease. Pharmacoepidemiol Drug Saf 2009, 18:1053-1063.
47. Rosemann T., Laux G., Kuehlein T. Osteoarthritis and functional disability: results of a cross sectional study among primary care patients in Germany. BMC Musculoskelet Dis 2007, 8:79.
48. Rosemann T., Laux G., Szecsenyi J., Wensing M., Grol R. Pain and osteoarthritis in primary care: factors associated with pain perception in a sample of 1,021 p.tients. Pain Med 2008, 9:903-910.
49. Sacks J.J., Luo Y.H., Helmick C.G. Prevalence of specific types of arthritis and other rheumatic conditions in the ambulatory health care system in the United States, 2001-2005. Arthritis Care Res 2010, 62(4):460-464.
50. Sharma L., Cahue S., Song J., Hayes K., Pai Y.C., Dunlop D. Physical functioning over three years in knee osteoarthritis: role of psychosocial, local mechanical, and neuromuscular factors. Arthritis Rheum 2003, 48:3359-3370.
51. Solomon D.H., Glynn R.J., Rothman K.J., Schneeweiss S., Setoguchi S., Mogun H., et al. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum 2008, 59:1097-1104.
52. Strand V. Patients with cardiovascular risk receiving low dose aspirin, is a COX-2 selective agent preferable to nsNSAIDs for antiinflammatory therapy?. Lancet 2007, 370:2138-2157.
53. Thompson M.S. Willingness to pay and accept risks to cure chronic disease. Am J Public Health 1986, 76:392-396.
54. Buominen U., Blom M., Hirvonen J., Seitsalo S., Lehto M., Paavolainen P., et al. The effect of comorbidities on health related quality of life in patients placed on the waiting list for total joint replacement. Health Qual Life Outcomes 2007 Mar 15, 5:16. 10.1186/1477-7525-5-16.
55. Van Dijk G.M., Veenhof C., Schellevis F. Comorbidity, limitations in activities and pain in patients with osteoarthritis of the hip or knee. BMC Musculoskelet Disord 2008 Jun 26, 9:95. 10.1186/1471-2474-9-95.
56. Woolf A.D., Pfleger B. Burden of major musculoskeletal conditions: policy and practice. Bone and joint decade 2000-2010. Bull World Health Organ 2003, 81:646-656.
57. Zhang W., Moskowitz R.W., Nuki G., Abramson S., Altman R.D., Arden N., et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008, 16:137-162.